Abstracts tagged "Sjogren’s syndrome and clinical research"

Abstract Number: 1784 • 2017 ACR/ARHP Annual Meeting
The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjögren’s Syndrome: A Phase IIa Double-Blind, Placebo-Controlled Randomized Trial
Benjamin Fisher¹, Margit Zeher², Wan-Fai Ng³, Michele Bombardieri⁴, Maximilian Posch⁵, Athena S Papas⁶, Arwa M Farag⁶, Thomas Daikeler⁷, Bettina Bannert⁸, Alan J. Kivitz⁹, Steven E. Carsons¹⁰, David A. Isenberg¹¹, Francesca Barone¹², Simon Bowman¹³, Pascal Espie¹⁴, Grazyna Wieczorek¹⁴, Pierre Moulin¹⁴, David Floch¹⁴, Cyrielle Dupuy¹⁴, Xiaohui Ren¹⁴, Petra Faerber¹⁴, Andrew M Wright¹⁵, Hans Ulrich Hockey¹⁵, Michael Rotte¹⁴, James S. Rush¹⁵ and Peter Gergely¹⁴, ¹Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ²Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ³Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ⁵Charité Research Organisation GmbH, Berlin, Germany, ⁶Tufts University, Boston, MA, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸University Hospital Basel, Basel, Switzerland, ⁹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ¹⁰NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ¹¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ¹⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, ¹⁵Novartis Pharmaceuticals Corporation, Basel, Switzerland
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a systemic, progressive autoimmune disease characterized by formation of ectopic germinal centers in exocrine glands and secretory gland dysfunction.…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.